The Efficacy and Safety of Tocilizumab in the Treatment of Refractory Ocular Myasthenia Gravis in Pediatric Patients
Muscle & Nerve · 2026-12 · 74 (6) · 1627-1635
DOI: 10.1002/mus.70435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, online erschienen am 12.10.2026. Verfasst von Qing-Qing Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Myasthenia Gravis. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction/Aims Refractory pediatric ocular myasthenia gravis (OMG) remains difficult to manage. We evaluated tocilizumab's efficacy and safety in these patients.
Methods
In this single‐center, retrospective analysis of prospectively collected registry data from Tangdu Hospital (China), pediatric refractory OMG patients received intravenous tocilizumab (8 mg/kg every 4 weeks) for 16 weeks as add‐on therapy. Refractory disease required persistent symptoms despite adequate trials of ≥ 2 immunosuppressants, frequent relapses during glucocorticoid tapering, or intolerance of conventional oral immunosuppressants. The primary outcome was change in Myasthenia Gravis‐Activities of Daily Living (MG‐ADL) score from baseline to Weeks 4, 8, 12, and 16, analyzed using generalized estimating equations.
Results
All 10 patients (1 male, 9 females; median age 5.5 years, range 2–11) completed 16 weeks of follow‐up. Seven (70%) were positive for antiacetylcholine receptor antibody (AChR‐Ab). At Week 4, mean MG‐ADL score decreased from 3.4 to 2.5 (incidence rate ratio[IRR], 0.74; 95% CI, 0.54–0.99; p = 0.048), with further reduction to 1.5 at week 16 (IRR, 0.44; 95% CI, 0.24–0.80; p = 0.007). Similarly, mean Quantitative MG (QMG) score dropped from 4.7 at baseline to 3.0 at Week 4 (IRR, 0.64; 95% CI, 0.41–0.99; p = 0.048) and further to 1.9 at Week 16 (IRR, 0.40; 95% CI, 0.24–0.69; p = 0.001). By Week 16, 50% of patients achieved minimal symptom expression, and 50% reduced prednisone requirements. Tocilizumab was well‐tolerated with only one transient infusion‐related dizziness.
Discussion
These preliminary findings suggest that tocilizumab may offer a safe and effective treatment option for children with refractory OMG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, China.
ORCID-Profile: Qing-Qing Wang, Xiang-Qi Cao, Bi-Ying Zhang, Si-Jia Hao, Ting Chang, Zhe Ruan
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, Q. Q., Cao, X. Q., Zhang, B. Y., Huang, X. X., Hao, S. J., Chang, T., & Ruan, Z. (2026). The Efficacy and Safety of Tocilizumab in the Treatment of Refractory Ocular Myasthenia Gravis in Pediatric Patients. Muscle & Nerve, 74(6), 1627-1635. https://doi.org/10.1002/mus.70435
Vancouver
Wang QQ, Cao XQ, Zhang BY, Huang XX, Hao SJ, Chang T, et al. The Efficacy and Safety of Tocilizumab in the Treatment of Refractory Ocular Myasthenia Gravis in Pediatric Patients. Muscle & Nerve. 2026;74(6):1627-1635. doi:10.1002/mus.70435
BibTeX
@article{Wang2026,
author = {Wang, Qing-Qing and Cao, Xiang-Qi and Zhang, Bi-Ying and Huang, Xiao-Xi and Hao, Si-Jia and Chang, Ting and Ruan, Zhe},
title = {The Efficacy and Safety of Tocilizumab in the Treatment of Refractory Ocular Myasthenia Gravis in Pediatric Patients},
journal = {Muscle & Nerve},
year = {2026},
volume = {74},
number = {6},
pages = {1627--1635},
doi = {10.1002/mus.70435}
}
EUVIMED